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Background: Fine needle aspiration (FNA) is considered an excellent technique 
for documenting metastatic neuroendocrine tumors. This study aims to evaluate 
the accuracy of FNA in diagnosing metastatic NETs to the liver and determining 
the grade and origin of these metastases. 
Methods: Our laboratory information system was searched from 1997 to 2016 to 
identify all cases of metastatic NETs to the liver that were sampled by FNA. The 
cytopathology and surgical pathology reports as well as the patients' electronic 
medical records were reviewed. The cytohistologic type and grade of the 
metastatic NETs, as well as the site of the patient's primary were recorded. 
Results: High-grade NETs, including small cell and poorly differentiated 
neuroendocrine carcinomas, constituted 62% (167/271) of the cases, while low 
grade NETs, including well differentiated NET (grade1 and grade 2), 
pheochromocytomas, paragangliomas and carcinoid tumors of lung, constituted 
38% (104/271) of cases. The most common diagnosis was metastatic small cell 
carcinoma accounting for 45% (122/271) of cases. The most common primary 
sites were lung (44%; 119/271) followed by pancreas (19%; 51/271). The FNA 
diagnosis was confirmed by histopathology in 121 cases that had a concurrent 
biopsies or resection specimens. 
Conclusions: FNA is an accurate method for diagnosing metastatic NETs to the 
liver. There were significantly more high-grade (62%) than low-grade (38%) 
metastatic NETs to the liver. In our practice, lung (44%) and pancreas (19%) 
were the most common primary sites of metastatic NETs involving the liver. In 
16% of the cases, a primary site could not be established. 
 
 
 
 
 
 
 
 
 
 
 
Introduction:  
Neuroendocrine tumors are defined as neoplasms with predominant 
neuroendocrine differentiation.(1, 2) They are a diverse group of tumors that 
most commonly arise from the lung and gastrointestinal tract, but can arise from 
virtually any organ in the body.(3) Neuroendocrine tumors are a heterogeneous 
group of neoplasms for which varying terminologies are employed depending 
upon the specific anatomic site that is primarily involved. These terms include, 
but are not limited to, carcinoid tumors, islet cell tumors, small cell carcinomas, 
large cell carcinomas, pheochromocytomas, paragangliomas, and medullary 
carcinomas of the thyroid gland (1, 2). In the United States, neuroendocrine 
tumors are more commonly seen in African Americans and among males. 
Among Caucasians, the lung is the most common site for neuroendocrine tumors 
(32%) while the rectum is the most common site in blacks (4). 
The duality of blood supply to the liver makes it a favorable site for metastatic 
malignancies including metastatic neuroendocrine tumors. Neuroendocrine 
tumors (NETs) of the liver represent 1-5% of all liver tumors. The liver is the most 
common site for metastasis of neuroendocrine tumors originating from the 
gastrointestinal tract, pancreas and lung (2). With rare exceptions such as 
pancreatic neuroendocrine microadenomas, NETs are usually considered to be 
tumors with malignant potential (3, 5). NETs from the gastrointestinal tract, liver 
and pancreas are graded according to their mitotic count and/or Ki-67 
proliferation index as: grade 1 (less than two mitosis and/or Ki-67 < 3 %); grade 2 
(2- 20 mitosis and/or Ki-67 3- 20%) and grade 3 (> 20 mitosis and/or Ki-67 > 
20%) (5, 6). NETs of the lung are classified into low grade (typical carcinoid 
tumors), intermediate grade (atypical carcinoid tumors) and high grade (small 
and large cell neuroendocrine carcinomas) based on the mitotic count (<2, 2-10 
and >10), tumor necrosis and tumor morphology (small cells vs. large cell) (6, 7).  
The aim of this study is to evaluate the diagnostic accuracy of FNA in diagnosing 
metastatic NETs to the liver determining the grade and origin of these 
metastases. 
Material and methods: 
This research protocol was reviewed by our institute review board (IRB) and was 
approved with an exemption from full review, since the study was a retrospective 
analysis of clinical work that had been previously performed, involved no patient 
contact, and utilized de-identified patient data. Our laboratory information system 
was searched from 1997 to 2016 to identify all cases of metastatic NETs to the 
liver that were sampled by FNA. The search was conducted to include all cases 
that had been diagnosed as neuroendocrine tumors, neuroendocrine 
carcinomas, small cell carcinomas, large cell carcinomas, carcinoid tumors, 
insulinomas, paragangliomas and pheochromocytomas. The cytopathology 
reports and correlating surgical pathology reports, including concurrent biopsies 
and/or resections, when available, were reviewed. The cytohistologic type and 
grade of the metastatic NETs, as well as the site of the patient's primary were 
recorded. The site of the patient’s primary tumor was determined by reviewing all 
of the pathological, clinical and radiological data for each case.  
Results:  
Of the 271 patients included in the study, 160 were males (59%) and 111 were 
females (41%) with ages that ranged from 7 to 88 years. Table 1. High-grade 
NETs, including small cell and poorly differentiated neuroendocrine carcinomas, 
constituted 62% (167/271) of the cases, while well differentiated pancreatic and 
gastrointestinal NET (grade1 and grade 2), pheochromocytomas, paraganglioma 
and carcinoid tumor of lung, constituted 38% (104/271) of cases. The most 
common diagnosis was metastatic small cell carcinoma accounting for 45% 
(123/271) of the cases, followed by low-grade neuroendocrine tumors (G1, G2) 
37% (61/271), while pheochromocytoma and paraganglioma represented only 
1% (3/271) and 0.4% of cases (1/271) respectively. Table 2.  
Low grade well differentiated NETs are composed of uniform, monomorphic, 
small to medium sized cells arranged in loosely cohesive groups and single cells. 
The tumor cells are round or cuboid to plasmacytoid with eccentric or central 
nuclei and containing smooth nuclear membrane and uniformly and coarsely 
granular chromatin (salt and pepper chromatin). Nucleoli maybe present. The 
cytoplasm is scant to moderate and granular. Mitosis and necrosis is usually not 
present in the low grade NETs. (Figure 1) High grade NETs tends to show tumor 
cells with marked nuclear atypia, necrosis and frequent mitosis,but the nuclei still 
demonstrate a salt and pepper chromatin pattern. Small cell carcinomas consist 
of small to medium sized tumor cells arranged in a prominent single cell 
dispersed cellular pattern with occasional loosely cohesive groups. There is 
scant cytoplasm. The nuclei are oval, pleomorphic with salt and pepper 
chromatin without distinct nucleoli. There is prominent nuclear molding with 
frequent apoptosis and mitosis. (Figure 2)  
The most common primary sites were lung (44%; 119/271), followed by pancreas 
(19%; 51/271) and small intestine (8%; 21/271). Table 3. Among metastatic low-
grade neuroendocrine tumors, which included low-grade pancreatic and 
gastrointestinal neuroendocrine tumors (G1, G2), carcinoid and atypical carcinoid 
tumors, the pancreas was the most common primary site (37, 37%) followed by 
metastasis from unknown primary (23, 23%), and the small intestine (21, 21%). 
Table 4. The FNA diagnosis was confirmed by histopathology in all 121 cases 
that had concurrent surgical biopsies or resections. Concurrent core biopsies 
were performed on selected cases. In the majority of cases, the diagnoses were 
rendered based on direct smears with or without cell blocks and supported by 
ancillary immunocytochemical stains that were either performed on the cell block 
or on the direct smears through cell transfer technique. Chromogranin, 
synaptophysin and Ki67 were routinely performed on cases of which the tumor 
cells demonstrating neuroendocrine morphology. 
 
 Discussion:  
Tumors with neuroendocrine differentiation are a heterogeneous group of tumors 
that include carcinoid tumors, islet cell tumors, small cell carcinomas, large cell 
neuroendocrine carcinomas, pheochromocytomas, paragangliomas, medullary 
carcinomas of the thyroid, and others. According to the WHO classification, the 
term neuroendocrine tumor (NET) is the preferred term to refer to both carcinoid 
tumors of the gastrointestinal tract and islet cell tumors of the pancreas (6). 
However, carcinoid and atypical carcinoid tumors are still commonly used terms 
to describe low and intermediate grade neuroendocrine tumors of the lung (7).  
Two important somewhat overlapping pathologic parameters that must be 
evaluated for neuroendocrine tumors are grade and differentiation. 
Neuroendocrine tumors are considered well differentiated when they have a 
recognizable neuroendocrine architecture such as an organoid or nested growth 
pattern, contain neuroendocrine nuclear features characterized by finely granular 
chromatin as well as smooth nuclear membranes, and granular cytoplasm. 
These features are almost always associated with intense expression of the 
neuroendocrine immunohistochemical markers, synaptophysin and 
chromogranin. On cytology, these tumors are formed of loosely cohesive, 
monotonous, plasmacytoid cells with finely granular chromatin. As tumors 
become poorly differentiated, they lose the characteristic growth pattern and 
cellular morphology, start to resemble poorly differentiated non-neuroendocrine 
tumors, and exhibit weaker immunostaining for the neuroendocrine markers, 
especially for chromogranin (1). It is apparent that high-grade tumors, evident by 
high mitosis with or without necrosis, are also more likely to be poorly 
differentiated in nature.  However, some tumors do show a well differentiated 
architecture, while expressing a high mitotic count (>20/HPF) and a high Ki-67 
proliferation index (>20%) The term high-grade well-differentiated 
neuroendocrine tumors has been proposed for this situation (1, 8).  
For many years, fine needle aspiration cytology alone or in combination with core 
biopsy specimens has been used to diagnose both primary and metastatic liver 
tumors. According to Kuo et al (9) the sensitivity of FNA for the diagnosis of liver 
tumors is 78% while the specificity is 97%, with improvements in sensitivity to 
85% and 99% when FNA is combined with histological examination of core 
biopsies. According to that study, the reduced accuracy of FNA was attributed to 
difficulty in differentiating hepatocellular carcinoma from benign lesions. Tsai et al 
(10), however, reported a lower false negative rate in diagnosing liver malignancy 
compared to histology (12% and 16% respectively). Similarly, Chhieng claimed 
that FNA has almost 100% specificity and is superior to biopsy alone (11).   
In our study, only 45% of the cases (121/271) had correlating surgical specimens 
(including concurrent biopsies or later resections). In all 121 FNA cases with 
histologic follow-up, the histopathologic diagnoses agreed with the FNA 
diagnoses, confirming the reliability of FNA in diagnosing metastatic 
neuroendocrine tumors to the liver. There were no discrepancies between the 
FNA and histologic diagnoses in these cases.  
High-grade NETs, including small cell and poorly differentiated neuroendocrine 
carcinomas, constituted greater than 60% of the cases, with small cell carcinoma 
being the most common diagnosis (45%). According to the literature, the lung is 
the most common site of neuroendocrine tumors among white Americans, while 
the rectum is the most common site among blacks. Despite the fact that 
neuroendocrine tumors are more prevalent among blacks, given that 72% of 
Americans are white (72%, 2010 census)(12), the lung still accounted for the 
most common primary site for metastatic neuroendocrine tumors in the United 
States (3). Our study also confirmed that the lung is the most common primary 
origin of metastatic NETs to the liver (44%), far more common than the pancreas 
(19%), which was the second most common primary site. In this study, the 
pancreas was the most common primary site of the low-grade metastatic 
neuroendocrine tumors to the liver. Approximately 16% of metastatic NETs to the 
liver in this series had an unknown primary, which is in keeping with the range of 
11% to 18% reported in the literature (11).  
Conclusion  
FNA is an accurate method for the diagnosis of metastatic NETs to the liver. In 
fact, for those cases with follow-up histology, there were no discrepancies 
between the FNA and histologic diagnoses. There were significantly more high-
grade (62%) than low-grade (38%) metastatic NETs to the liver. In our practice, 
lung (44%), pancreas (19%) and small intestine (8%) were the most common 
primary sites of origin of NETs that metastasized to the liver. As reported by 
others, a primary site could not be established in a significant minority of patients 
(16%)  
References 
1. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic 
classification of neuroendocrine tumors: a review of nomenclature, 
grading, and staging systems. Pancreas 2010;39:707-712. 
 
2. Prosser JM, Dusenbery D. Histocytologic diagnosis of neuroendocrine 
tumors in the liver: A retrospective study of 23 cases. Diagnostic 
Cytopathol 1997;16:383-391. 
 
3. Klimstra DS. Pathology reporting of neuroendocrine tumors: essential 
elements for accurate diagnosis, classification, and staging. Semin Oncol 
2013;40:23-36. 
 
4. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, et al. 
Neuroendocrine tumor epidemiology. Cancer 2008;113:2655-2664. 
 
5. Kim JY, Hong S-M. Recent updates on neuroendocrine tumors from the 
gastrointestinal and pancreatobiliary tracts. Arch Pathol Lab Med 
2016;140:437-448. 
 
6. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO 
Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: 
International Agency for Research on Cancer, 2015. 
 
7. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, 
Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch 
FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao 
MS, Wistuba I; WHO Panel. The 2015 World Health Organization 
classification of lung tumors: impact of genetic, clinical and radiologic 
advances since the 2004 classification. J Thorac Oncol 2015;10:1243-
1260. 
 
8. Tang L, Shia J, Vakiani E, Dhall D, Klimstra D. High grade transformation 
of differentiated neuroendocrine neoplasms (NENs) of the 
enteropancreatic system-a unique entity distinct from de novo high grade 
neuroendocrine carcinoma (HGNECa) in pathogenesis and clinical 
behavior. Lab Invest 2008;88(Suppl 1):137A.  
 
9. Kuo F, Chen W, Lu S, Wang J, Eng H. Fine needle aspiration 
cytodiagnosis of liver tumors. Acta Cytol 2004;48:142-148. 
 
10. Tsai Y-Y, Lu S-N, Changchien C-S, Wang J-H, Lee C-M, Eng H-L, et al. 
Combined cytologic and histologic diagnosis of liver tumors via one-shot 
aspiration. Hepatogastroenterology 2001;49:644-647. 
 
11. Chhieng DC. Fine needle aspiration biopsy of liver–an update. World J 
Surg Oncol 2004;2:5. 
 
 
12. Humes K, Jones NA, Ramirez RR. "Overview of Race and Hispanic origin: 
2010 2010 Census Briefs." (2015).    
 
Figure legends:  
Figure 1. Smears of well-differentiated pancreatic NET predominantly show- 
dispersed single cells with moderate vacuolated cytoplasm (A, Diff-Quik stain). 
The tumor cells have eccentrically located nuclei with a characteristic finely 
stippled chromatin pattern (B, Papanicolaou stain). A similar morphology is seen 
in carcinoid tumors of the lung. The cells are loosely cohesive, with plasmacytoid 
appearance and granular cytoplasm (C, Papanicolaou stain). A common feature 
of low-grade neuroendocrine tumors is the formation of small clusters or rosettes 
of cells as seen in this NET of small intestine (D, Papanicolaou stain).  
 
Figure 2. Smears of small cell neuroendocrine carcinomas show extensive 
nuclear molding, crush artifact and frequent apoptotic bodies (A, Diff-Quik stain). 
The powdery and evenly distributed chromatin is characteristic (B, Papanicolaou 
stain). Large cell neuroendocrine carcinomas show cohesive sheets and single 
cells with large irregular nuclei, prominent nucleoli and more cytoplasm than is 
seen in small cell carcinoma (C, Papanicolaou stain). Cell block slides from large 
cell neuroendocrine carcinoma stain positively for synaptophysin and show a 
high Ki-67 proliferation index (D, E respectively).  
  
Table 1 
Demographic Characteristics of the Patients  
with Metastatic Neuroendocrine Tumors to the Liver   Number Percent 
Gender Male 160 59% Female 111 41%  
Ethnic group White 241 88.9% African American 22 8.1% Hispanic 1 0.4% Other 3 1.1% Unknown 4 1.5%  
Age Minimum     7 years Maximum 88 years Mean (SD) 64 (12) years    
Table 2 
The Cytohistological Type of Metastatic Neuroendocrine Tumors to the Liver 
 Grade and Subtype Number Percent 
High Grade   Small cell carcinoma 123 45.4 % Large cell carcinoma 12 4.4 % Neuroendocrine tumor,  high grade (G3) 30 11.1% Mixed small cell and large cell 2 0.7% 
Subtotal 167 61.6% 
   
Low Grade   Neuroendocrine tumors,  low grade (G1, G2) 100 36.9% Pheochromocytoma 3 1.1 % Paraganglioma 1 0.4 % 
Subtotal 104 38.4%    
Total 271 100 %  
  
Table 3 
Primary Site for Metastatic Neuroendocrine Tumors to the Liver  
 Number Percent Lung 119 43.9 % Pancreas 51 18.8 % Small intestine 21 7.8 % Large Intestine 8 3.0 % Adrenal  3 1.1 % Prostate 5 1.8 % Vagina 1 0.4 % Appendix 1 0.4 % Stomach 2 0.7 % Esophagus 1 0.4 % Paraortic 1 0.4 % Soft palate 1 0.4 % GIT NOS 2 0.7 % Testes 1 0.4 % Bladder 2 0.7 % Liver 1 0.4 % Unknown 43 15.9 % Unavailable data 8 3.0 %    
Table 4 
Primary Site for Metastatic Low-Grade (G1, G2)  
Neuroendocrine Tumors to the Liver  
 Number Percent Lung 6 6% Pancreas 37 37% Small intestine 21 21% Large Intestine 3 3% Vagina 1 1% Appendix 1 1% Stomach 2 2% GIT NOS 2 2% Liver 1 1% Unknown 23 23% Unavailable data 3 3%  
 
   
